These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33367961)

  • 1. Population Pharmacodynamic Modeling Using the Sigmoid E
    Proost JH; Eleveld DJ; Struys MMRF
    AAPS J; 2020 Dec; 23(1):10. PubMed ID: 33367961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A technique for population pharmacodynamic analysis of concentration-binary response data.
    Bailey JM; Gregg KM
    Anesthesiology; 1997 Apr; 86(4):825-35. PubMed ID: 9105227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability of pharmacodynamic analysis by logistic regression: mixed-effects modeling.
    Lu W; Ramsay JG; Bailey JM
    Anesthesiology; 2003 Dec; 99(6):1255-62. PubMed ID: 14639136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.
    Ebling WF; Levy G
    Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of mixture modeling with count data using NONMEM.
    Frame B; Miller R; Lalonde RL
    J Pharmacokinet Pharmacodyn; 2003 Jun; 30(3):167-83. PubMed ID: 14571690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parameter estimation for sigmoid E
    Choe S; Lee D
    Transl Clin Pharmacol; 2017 Jun; 25(2):74-84. PubMed ID: 32133323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
    Fullerton T; Forrest A; Levy G
    J Pharm Sci; 1996 Jun; 85(6):600-7. PubMed ID: 8773956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic parameter estimation: population size versus number of samples.
    Girgis S; Pai SM; Girgis IG; Batra VK
    AAPS J; 2005 Oct; 7(2):46. PubMed ID: 16353905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficiency concept in pharmacodynamics.
    Alván G; Paintaud G; Wakelkamp M
    Clin Pharmacokinet; 1999 May; 36(5):375-89. PubMed ID: 10384860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the anesthetic effect of ropivacaine after a femoral nerve block in orthopedic patients: a population pharmacokinetic-pharmacodynamic analysis.
    Gaudreault F; Drolet P; Fallaha M; Varin F
    Anesthesiology; 2015 May; 122(5):1010-20. PubMed ID: 25790027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of pharmacodynamic analysis by logistic regression: a computer simulation study.
    Lu W; Bailey JM
    Anesthesiology; 2000 Apr; 92(4):985-92. PubMed ID: 10754617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of type I error rates when modeling ordered categorical data in NONMEM.
    Wählby U; Matolcsi K; Karlsson MO; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Feb; 31(1):61-74. PubMed ID: 15346852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine.
    Chan Kwong AHP; Calvier EAM; Fabre D; Gattacceca F; Khier S
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):431-446. PubMed ID: 32535847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technique for quantifying the duration of intravenous anesthetic effect.
    Bailey JM
    Anesthesiology; 1995 Nov; 83(5):1095-103. PubMed ID: 7486161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter-study variability in population pharmacokinetic meta-analysis: when and how to estimate it?
    Laporte-Simitsidis S; Girard P; Mismetti P; Chabaud S; Decousus H; Boissel JP
    J Pharm Sci; 2000 Feb; 89(2):155-67. PubMed ID: 10688745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.
    Romberg R; Olofsen E; Sarton E; den Hartigh J; Taschner PE; Dahan A
    Anesthesiology; 2004 Jan; 100(1):120-33. PubMed ID: 14695733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
    Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacodynamic modeling and covariate detection for central neural blockade.
    Schnider TW; Minto CF; Bruckert H; Mandema JW
    Anesthesiology; 1996 Sep; 85(3):502-12. PubMed ID: 8853080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children.
    Brown RD; Kearns GL; Wilson JT
    J Pharmacokinet Biopharm; 1998 Oct; 26(5):559-79. PubMed ID: 10205771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.